About Quratis
Quratis is a company based in Seoul (South Korea) founded in 2016. Quratis offers products and services including QTP101, QTP104, CPP Platform, Peptide Nucleic Acid Complexes, and CMO&CDMO Services. Quratis operates in a competitive market with competitors including Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
- Headquarter Seoul, South Korea
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name (주)큐라티스
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
$253.44 K (USD)-63.71as on Dec 31, 2024
-
Net Profit
-$17.81 M (USD)-54.6as on Dec 31, 2024
-
EBITDA
-$10.32 M (USD)-25.65as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Quratis
Quratis offers a comprehensive portfolio of products and services, including QTP101, QTP104, CPP Platform, Peptide Nucleic Acid Complexes, and CMO&CDMO Services.
Tuberculosis vaccine combining antigens and immune enhancers.
COVID-19 mRNA vaccine for viral protection.
Platform for cell-penetrating peptides in drug transport.
Complexes for nucleic acid binding and therapeutic applications.
Custom services for biological product development and production.
Funding Insights of Quratis
Investments & Acquisitions by Quratis
Investment portfolio details for Quratis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Quratis
Detailed financials for Quratis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Quratis Comparisons
Peer comparison for Quratis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Quratis
Quratis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
|
|
| Locked | Locked | Locked |
Late-stage biopharma antibiotics for gynecological infections are developed.
|
|
| Locked | Locked | Locked |
Vaccines for viral infections are developed by the company.
|
Detailed competitors of Quratis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Quratis
Complete news archive for Quratis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Quratis
Quratis was founded in 2016 and raised its 1st funding round 7 years after it was founded.
Quratis is headquartered in Seoul, South Korea.
Kwan-Goo Cho is the current CEO of Quratis.
Annual revenue of Quratis is $253.44K as on Dec 31, 2024.
Quratis was founded in 2016 in Seoul, South Korea, within the biotechnology sector. Focus is placed on developing vaccines and cell therapies to address tuberculosis. The lead program involves the ID93 fusion protein paired with the GLA-SE adjuvant, which has completed Phase I clinical trials. This approach aims to strengthen immune responses generated by the BCG vaccine, supporting ongoing efforts in infectious disease treatment.
Quratis's top competitors include Insmed, Basilea and Eligo Bioscience.
Quratis offers QTP101, QTP104, CPP Platform, Peptide Nucleic Acid Complexes, and CMO&CDMO Services.